title: [Meglumine acridonacetate and complex therapy of patients with newly identified advanced pulmonary tuberculosis].
abstract: Clinical and immunological efficacy of meglumine acridonacetate (cycloferon) tablets was evaluated in complex treatment of patients with newly diagnosed advanced pulmonary tuberculosis. It was shown that the use of cycloferon according to our scheme increased the efficacy of the therapy (earlier disappearance of the disease symptoms and bacteria isolation, shorter-terms of cavern healing, more pronounced positive radiographic dynamics vs. the patients under the etiotropic therapy). The use of cycloferon normalized the number of gamma interferon receptors, increased the gamma interferon serum levels, reduced the incidence of the side effects (liver damage) due to the use of TB drugs. Such a use of cycloferon was cost effective. The use of sycloferon is possible in the complex treatment of outpatients with advanced pulmonary tuberculosis.
authors.forename: N S
authors.initials: NS
authors.lastname: Pravada
authors.forename: A M
authors.initials: AM
authors.lastname: Budritskiĭ
authors.forename: D S
authors.initials: DS
authors.lastname: Sukhanov
mesh_terms: D000166:Acridines / Q000627:therapeutic use*; D000293:Adolescent; D000328:Adult; D000368:Aged; D015703:Antigens, CD / Q000378:metabolism; D000995:Antitubercular Agents / Q000627:therapeutic use; D015415:Biomarkers / Q000378:metabolism; D056486:Chemical and Drug Induced Liver Injury / Q000517:prevention & control; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007369:Interferon Inducers / Q000627:therapeutic use*; D007371:Interferon-gamma / Q000378:metabolism; D008099:Liver / Q000187:drug effects / Q000473:pathology; D008168:Lung / Q000187:drug effects* / Q000276:immunology / Q000382:microbiology / Q000473:pathology; D008214:Lymphocytes / Q000187:drug effects / Q000276:immunology / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009169:Mycobacterium tuberculosis / Q000187:drug effects / Q000254:growth & development; D017471:Receptors, Interferon / Q000378:metabolism; D013607:Tablets; D016896:Treatment Outcome; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy* / Q000276:immunology / Q000382:microbiology / Q000473:pathology
chemical_list: D000166:Acridines; D015703:Antigens, CD; D000995:Antitubercular Agents; D015415:Biomarkers; D007369:Interferon Inducers; D017471:Receptors, Interferon; D013607:Tablets; D007371:Interferon-gamma; C026430:10-carboxymethyl-9-acridanone